Related Experiment Video
Updated: Dec 18, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Kidney and liver dysfunction in cardiogenic shock
1Heart and Lung Center, Cardiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Insights
Organ dysfunction, particularly kidney and liver issues, significantly increases mortality in cardiogenic shock patients. Early detection and monitoring of these dysfunctions are crucial for improved patient outcomes.
Area of Science:
- Cardiology
- Critical Care Medicine
- Nephrology
- Hepatology
Background:
- Cardiogenic shock frequently leads to multiorgan failure, with renal and liver dysfunction being common and increasing mortality.
- Despite advances in intensive care and revascularization, mortality in cardiogenic shock remains high.
- Organ dysfunction is a hallmark of cardiogenic shock, necessitating focused management strategies.
Purpose of the Study:
- To review the prevalence, manifestation, management, and clinical impact of kidney and liver dysfunction in cardiogenic shock.
- To highlight the critical role of monitoring organ function in cardiogenic shock patients.
- To discuss the association between organ dysfunction and mortality in cardiogenic shock.
Main Methods:
- Review of current literature on cardiogenic shock and organ dysfunction.
- Discussion of diagnostic criteria and classification of renal and liver injury.
- Exploration of risk prediction models and biomarkers in cardiogenic shock.
Main Results:
- Kidney and liver dysfunction markedly increase mortality in cardiogenic shock.
- Active monitoring of organ function is essential for management and risk assessment.
- Biomarkers may improve risk prediction and serve as future treatment targets.
Conclusions:
- Monitoring renal and hepatic function is vital for managing cardiogenic shock patients.
- Identifying and classifying organ injury aids in mortality risk assessment.
- Further research into biomarkers may enhance treatment strategies for cardiogenic shock.
Purpose Of Review:
Organ dysfunction is a key feature of cardiogenic shock. Active revascularization and contemporary management in intensive care has improved prognosis in cardiogenic shock, but mortality is still unacceptably high. This review will discuss the prevalence, manifestation, management and clinical impact of kidney and liver dysfunction in cardiogenic shock.
Recent Findings:
Patients with cardiogenic shock more frequently have several comorbidities that make them at risk of developing multiorgan failure, including renal and liver dysfunction. Kidney and liver injury and dysfunction will markedly increase mortality of patients with cardiogenic shock. Management requires active monitoring of organ function and knowledge of criteria for detection and classification of organ injury. The SOFA score for prediction of mortality in the critically ill incorporates organ injury and can be used also in cardiogenic shock, but risk prediction models specific for cardiogenic shock exist. Biomarkers reflecting different pathways activated in cardiogenic shock correlate with severity of organ dysfunction and may improve risk prediction in cardiogenic shock. Preliminary data suggest that they can even be future treatment targets.
Summary:
Monitoring renal and hepatic function and identifying injury and dysfunction of these organs is essential for the management and mortality risk assessment of patients in cardiogenic shock.
Related Concept Videos
Heart Failure Drugs: Diuretics
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

